European Medicines Agency Reorganizes - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

European Medicines Agency Reorganizes


The European Medicines Agency (EMA) has released details about its restructuring. The reorganization, first announced in December 2012 and expected to be completed in 2014, focuses on supporting scientific work of the various EMA committees, sharing information throughout the European Union’s regulatory system, and meeting the needs of stakeholders and partners.

The new structure introduces an operating model for managing drugs through their entire lifecycle, with separation of the scientific and procedure management. EMA will increase the number and complexity of applications being handled by the Agency’s committees to reinforce the robustness and quality of the Agency’s output. The reorganization creates four new divisions: Human Medicines Research and Development Support, Human Medicines Evaluation, Procedure Management and Business Support, and Inspections and Human Medicines Pharmacovigilance. A new Division for Stakeholders and Communication will provide improved coordination of the Agency’s relations with patients and healthcare professionals, support for small and medium-sized enterprises, and a dedicated communication service.

“The changes announced today will reshape the EMA so that it is ready to handle future challenges and seize opportunities,” said Professor Guido Rasi, EMA Executive Director in a press release. “My aim is to give our scientific committees the best possible support, alongside the expertise from the national agencies, to help them keep delivering high-quality, consistent opinions. These changes will enable us to use our resources more efficiently and effectively and ensures that the Agency is better prepared for future legislative and policy challenges.”

Source: European Medicines Agency

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here